Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)

Parexel collaborates with Japanese Foundation for cancer research

Collaboration streamlines patient access to oncology clinical trials

Lupin receives USFDA’s approval or Propranolol Hydrochloride Extended-Release Capsules USP

Unichem receives ANDA approval for Doxazosin Tablets

Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure

Deloitte expands Quartz AI suite with Atlas AI for drug discovery

Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design

Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays

Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio

Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union

Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole

Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US